Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/11568
Title: Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
Authors: Wright, David
Poon, Liona C
Rolnik, Daniel L
Syngelaki, Argyro
Delgado, Juan Luis
Vojtassakova, Denisa
de Alvarado, Mercedes
Kapeti, Evgenia
Rehal, Anoop
Pazos, Andrea
Carbone, Ilma Floriana
Dutemeyer, Vivien
Plasencia, Walter
Papantoniou, Nikos
Nicolaides, Kypros H
Keywords: Aspirin for Evidence-Based Preeclampsia Prevention trial;aspirin;compliance;first-trimester screening;mean arterial blood pressure;placental growth factor;prediction;preeclampsia;pregnancy-associated plasma protein A;pyramid of pregnancy care;treatment effect;uterine artery Doppler
metadata.dc.subject.mesh: Adult
Aspirin
Double-Blind Method
Ethnicity
Evidence-Based Medicine
Female
Humans
Logistic Models
Maternal Age
Medication Adherence
Placenta Growth Factor
Platelet Aggregation Inhibitors
Pre-Eclampsia
Pregnancy
Pregnancy Trimester, First
Pregnancy-Associated Plasma Protein-A
Premature Birth
Pulsatile Flow
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Smoking
Treatment Outcome
Uterine Artery
Young Adult
Issue Date: 6-Sep-2017
Abstract: The Aspirin for Evidence-Based Preeclampsia Prevention trial was a multicenter study in women with singleton pregnancies. Screening was carried out at 11-13 weeks' gestation with an algorithm that combines maternal factors and biomarkers (mean arterial pressure, uterine artery pulsatility index, and maternal serum pregnancy-associated plasma protein A and placental growth factor). Those with an estimated risk for preterm preeclampsia of >1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg/d) vs placebo from 11-14 until 36 weeks' gestation. Preterm preeclampsia with delivery at 1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg/d) vs placebo from 11-14 until 36 weeks' gestation. Preterm preeclampsia with delivery at We sought to examine the influence of compliance on the beneficial effect of aspirin in prevention of preterm preeclampsia in the Aspirin for Evidence-Based Preeclampsia Prevention trial. This was a secondary analysis of data from the trial. The proportion of prescribed tablets taken was used as an overall measure of compliance. Logistic regression analysis was used to estimate the effect of aspirin on the incidence of preterm preeclampsia according to compliance of Preterm preeclampsia occurred in 5/555 (0.9%) participants in the aspirin group with compliance ≥90%, in 8/243 (3.3%) of participants in the aspirin group with compliance The beneficial effect of aspirin in the prevention of preterm preeclampsia appears to depend on compliance.
URI: http://hdl.handle.net/10668/11568
metadata.dc.identifier.doi: 10.1016/j.ajog.2017.08.110
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons